The Colony-based CerpassRx has been acquired by Maryland-based LucyRx, a fast-scaling, next-generation pharmacy benefits manager.
CerpassRx is a division of Nomi Health, a direct healthcare company. Terms of the deal, which is slated to close in the third quarter, were not disclosed.
“Joining LucyRx is a natural next step for our clients and our team,” John Nicolosi, interim president of CerpassRx, said in a statement. “Our shared values of clarity, accountability, and care make this a powerful combination. We’re excited to extend our impact with the support of LucyRx’s technology, scale, and clinical approach.”
The combination brings together CerpassRx’s “proven track record of service and cost containment” with LucyRx’s technology-driven clinical approach, all under a shared vision for “smarter, more transparent prescription care,” LucyRx said.
“We’re combining two organizations who are relentlessly focused on performance, innovation and compassion, and continually raising the bar for what clients and members can expect from a PBM,” LucyRx CEO David Blair said in a statement. “CerpassRx is a strong cultural and strategic fit for LucyRx.”
By combining LucyRx’s tech-driven clinical model with CerpassRx’s service-first approach and cost containment expertise, LucyRx said the partnership creates a more impactful PBM solution—”one that delivers smarter care, stronger savings, and a seamless experience for clients and members alike.”
Advantages of the combined platform
LucyRx and CerpassRx said each brings distinct but highly complementary capabilities to the combination.
LucyRx offers a proprietary Formulary Marketplace, a broad Connected Specialty Care Network that integrates leading health systems and specialty pharmacies, and personalized clinical guidance through its Care Guide model. Its clinical programs focused on high-impact areas like GLP-1 therapies and Women’s Health deliver smarter, more proactive prescription care for members.
CerpassRx said it excels in driving down prescription costs through proprietary cost containment strategies, flexible formulary design, and tailored clinical programs. With a high-touch service model, it delivers rapid implementation and measurable outcomes, earning a reputation for disrupting the traditional PBM model and building long-term trust with clients and members.
Together, they form a national PBM platform that is “performance-driven, clinically forward, and relentlessly focused on serving clients and members with clarity and accountability,” the companies said.
Also, the combination aims to create a more impactful platform for clients and members that offers:
- Smarter Cost Containment: CerpassRx’s proven cost-saving programs layered onto LucyRx’s transparent pricing and formulary marketplace.
- Stronger Member Support: Integrated clinical teams, anchored by LucyRx’s Care Guides and CerpassRx’s personalized service culture.
- Scalable Innovation: LucyRx’s AI-powered insights and infrastructure amplify CerpassRx’s high-touch service, making care more personal at scale.”
‘Transparent, tech-forward pharmacy care’
“We’re combining two organizations who are relentlessly focused on performance, innovation, and compassion,” Blair said, “and continually raising the bar for what clients and members can expect from a PBM.”
Mark Newman, CEO and Co-Founder of Nomi Health, said the combination is a good fit.
“We’re proud of the foundation CerpassRx has built, and we believe LucyRx is the right partner to take it even further,” Newman said. “This agreement reflects a shared vision for more transparent, tech-forward pharmacy care and we’re confident it will create long-term value for clients, members, and the broader market.
The companies said there will be no changes to service, support, or operations as a result of this agreement.
“Clients expect more from their PBM, and they should,” Susan Thomas, chief commercial officer at LucyRx, said in a statement. “Together with CerpassRx, we expand both the reach and depth of our solutions. And we’ll deliver an experience that is more personal, more affordable and more clinically impactful.”
As part of this agreement, Nomi Health and LucyRx will continue working together to support their shared clients and build on current partnership efforts to lower pharmacy costs for both employers and their members, advancing a shared commitment to bring more transparency, innovation, and affordability to healthcare, the companies said.
Don’t miss what’s next. Subscribe to Dallas Innovates.
Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.
R E A D N E X T
-
Combining cutting-edge research and real-world applications, the UT Dallas professor transforms public health with innovations in detection technology, including “a check engine light” for the human body. In collaboration with EnLiSense, the company she cofounded, Dr. Prasad combines chemistry with software and hardware to bring the technology to life as market-ready devices.
-
"Our mission is to help those who help others," says Pieces Technologies CEO Dr. Ruben Amarasingham. With $25M in growth funding, Dallas-based Pieces is gearing up to transform hospital care with AI that streamlines clinical workflows and eases the load on care teams.
-
Qualthera, a new company founded by entrepreneur Donald Prentiss, has made its first acquisition—Central Drug in Victoria, Texas—and set its sights on Dallas for its second. Prentiss sees an opportunity in the shifting pharmacy landscape, where changes, including downsizing by large chains, have created service gaps that independent pharmacies could fill.
-
Take Command’s new COO will sharpen operations as the company builds on national momentum around Individual Coverage Health Reimbursement Arrangements (ICHRAs), with advancing legislation that could codify the model into federal law.
-
When a hotline failed her, 16-year-old Bhuvika Tripuraneni built her own answer. Meet the Frisco teen using AI to help Gen Z cope—and coding toward a future in bioinformatics.
